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Reducing serum low-density lipoprotein (LDL) cholesterol
by statins has been shown to reduce cardiovascular events and
mortality in secondary and primary prevention trials (1-3).
Further reduction of serum LDL cholesterol in patients
after an acute coronary syndrome treated with statins by
ezetimibe (4) and in patients with cardiovascular disease
treated with statins by the proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitor evolocumab (5) have been
demonstrated to further reduce cardiovascular events .
Numerous epidemiological studies have demonstrated an
inverse association between serum high-density lipoprotein
(HDL) cholesterol levels and cardiovascular outcomes
(6,7). However, randomized, placebo-controlled trials have
not shown that increase of serum HDL cholesterol levels
by drug therapy improves cardiovascular outcomes. In
3,414 patients with cardiovascular disease receiving intensive
statin therapy randomized to receive niacin or placebo, at
2 years after therapy, niacin increased the median serum HDL
cholesterol level from 35 to 42 mg/dL, reduced the serum
LDL cholesterol level from 74 to 62 mg/dL, and reduced
the serum triglyceride level from 164 to 122 mg/dL (8).
At 3-year median follow-up, cardiovascular outcomes had
occurred in 16.4% of patients treated with niacin versus
16.2% of patients treated with placebo (8). In 25,673 patients
with cardiovascular disease treated with statin therapy
randomized to 2 grams of extended-release niacinlaropiprant or placebo, at 3.9 years follow-up after therapy,
compared with placebo, niacin-laropiprant increased serum
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HDL cholesterol by 6 mg/dL and reduced serum LDL
cholesterol by 10 mg/dL (9). Compared with placebo,
niacin-laropiprant did not reduce cardiovascular events but
increased serious adverse events (9).
The cholesteryl ester transfer protein (CETP) inhibitors
torcetrapib, dalcetrapib, evacetrapib, and anacetrapib
inhibit the enzyme responsible for transferring cholesterol
esters from HDL to very-low-density lipoprotein (VLDL)
or LDL. These drugs have been shown to increase serum
HDL cholesterol and reduce serum LDL cholesterol levels.
However, at 15.1-year follow-up of 1,978 persons in the
Framingham Heart Study, lower plasma CETP activity was
associated with greater cardiovascular disease risk, which
challenges the concept that CETP inhibition may lower
cardiovascular disease risk (10). There are also conflicting
data that genetic polymorphisms causing a lower mass or
activity of CETP are associated with higher serum HDL
cholesterol levels, lower serum LDL cholesterol levels, and
a lower risk of coronary heart disease (11,12).
The Investigation of Lipid Level Management
to Understand its Impact in Atherosclerotic Events
(ILLUMINATE) trial was a prospective randomized,
double-blind study which randomized 15,067 patients,
mean age 61.3 years, at high cardiovascular risk treated with
atorvastatin to reduce the serum LDL cholesterol level to
less than 100 mg/dL to receive torcetrapib 60 mg daily plus
atorvastatin or atorvastatin only (13). At 12-month follow-up,
torcetrapib increased serum HDL cholesterol 72.1%
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and reduced serum LDL cholesterol 24.9%. However,
torcetrapib also increased systolic blood pressure by
5.4 mm Hg and caused a decrease in serum potassium and
an increase in serum sodium, bicarbonate, and aldosterone
levels. At a median follow-up of 550 days, the primary
outcome of time to death from coronary heart disease,
nonfatal myocardial infarction, stroke, or hospitalization
for unstable angina pectoris was increased 25% (95% CI,
9% to 44%; P=0.001) by torcetrapib (13). Torcetrapib also
increased all- cause mortality by 58% (95% CI, 1.14 to
2.19; P=0.006) (13). The off-target pharmacologic effects
contributed to the increase in cardiovascular events and
in all-cause mortality. It has also been suggested that
CETP inhibition may cause HDL particles which are
nonfunctional or even proatherogenic (14). Recent data
showed that torcetrapib increased the HDL subclasses
LpA-I and LpA-II equally and the apoC-III content of
HDL without affecting the apoB-containing subclasses,
supporting that the adverse effects of torcetrapib were not
due to disturbances in lipoprotein transport (15).
The effects of dalcetrapib in patients with a recent
acute coronary syndrome (dal-OUTCOMES ) study
randomized 15,871 patients, mean age 60.2 years, with
a recent acute coronary syndrome to receive the CETP
inhibitor dalcetrapib 600 mg daily or to receive placebo (16).
Statins were used in 98% of patients at the time of
randomization. At the time of randomization, the mean
serum HDL cholesterol level was 42 mg/dL, and the mean
serum LDL cholesterol level was 76 mg/dL. During the
study, the serum HDL cholesterol level increased from
baseline by 4% to 11% in the placebo group and by 31%
to 40% in the group treated with dalcetrapib. Dalcetrapib
caused a minimal effect on serum LDL cholesterol levels.
Compared with placebo, dalcetrapib increased the median
C-reactive protein level by 0.2 mg/L and the mean systolic
blood pressure by 0.6 mmHg. At a median follow-up of
31 months, compared with placebo, dalcetrapib
insignificantly increased the primary endpoint of death
from coronary heart disease, nonfatal myocardial infarction,
ischemic stroke, unstable angina pectoris, or cardiac arrest
with resuscitation by 4% (16).
The Randomized Evaluation of the Effects of
Anacetrapib through Lipid-modification (REVEAL) trial is
an ongoing trial of 30,449 patients, mean age 67 years, with
cardiovascular disease being treated with atorvastatin for an
average of at least 4 years who were randomized to receive
the CTEP inhibitor anacetrapib 100 mg daily or to receive
placebo (17). At the time of randomization, the mean
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plasma HDL cholesterol was 40 mg/dL, and the mean
plasma LDL level was 61 mg/dL. Results are anticipated in
2017 (17).
This editorial was written to discuss the results of the
recently published paper on the Assessment of Clinical
Effects of Cholesteryl Ester Protein Inhibition with
Evacetrapib in Patients at a High Risk for Vascular Outcomes
(ACCELERATE) trial (18). This study was a multicenter,
randomized , double-blind, placebo-controlled phase3
trial which included 12,092 patients, mean age 64.9 years
(46.5% men), who had at least one of the following medical
conditions: an acute coronary syndrome within the prior 30 to
365 days (30.2%), cerebrovascular atherosclerotic disease
(11.9%), peripheral vascular arterial disease (13.9%), or
diabetes mellitus with coronary arterial disease (64.4%) (18).
Statins were used to treat 96.5% of the patients.
Antihypertensive drug therapy was used to treat 87.3% of
the patients. The baseline serum HDL cholesterol level
was 45.3 mg/dL, LDL cholesterol level was 81.4 mg/dL,
and triglycerides was 128 mg/dL. The patients were
randomized to receive evacetrapib 130 mg daily or to
receive matching placebo. The primary efficacy endpoint
was the first occurrence of any component of the composite
of cardiovascular death, myocardial infarction, stroke,
coronary revascularization, or hospitalization for angina
pectoris. At 3 months, the mean serum HDL cholesterol
was increased by 133.2% with evacetrapib and by 1.6%
with placebo, and the mean serum LDL cholesterol level
was reduced by 31.1 % with evacetrapib and increased by
6.0% with placebo. At a median follow-up of 26 months,
a primary end point event occurred in 12.9% of patients
treated with evacetrapib versus in 12.8% of patients treated
with placebo (18).
These data demonstrated that evacetrapib significantly
increased serum HDL cholesterol and significantly reduced
serum LDL cholesterol. However, despite these favorable
effects on serum HDL cholesterol and on serum LDL
cholesterol, evacetrapib did not reduce cardiovascular
events in patients with high-risk cardiovascular disease (18).
There is a large body of data from animal intervention
studies and from human genetic studies supporting that
CTEP inhibition is antiatherogenic and, therefore, will
reduce cardiovascular events in humans (19). However, the
lack of consistent data about the consequences of genetically
defined CTEP deficiency, the variability in lipid parameters
in patients treated with the different CETP inhibitors,
and the negative clinical outcomes of the clinical trials
reported support that lowering of CTEP will not reduce
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cardiovascular events (20).
The results from the ILLUMINATE trial (13), the
dal-OUTCOMES trial (16), and the ACCELERATE
trial (18) support that CTEP inhibition will not reduce
cardiovascular events in humans. We are awaiting the
clinical outcome data from the REVEAL trial to know
whether or not the CETP inhibitor anacetrapib will reduce
cardiovascular events.
Data from the niacin trials (8,9) and from the 3
completed large-scale CTEP inhibitor trials (13,16,18) have
clearly demonstrated that raising serum HDL cholesterol
does not improve cardiovascular outcomes. Future HDL
cholesterol trials may need to measure HDL subclasses and
HDL functionality (21). A low HDL cholesterol level may
only be a marker of cardiovascular disease. Increasing HDL
cholesterol so far by pharmacologic therapy has not been
shown to reduce cardiovascular events. Although lowering
serum LDL cholesterol by statins (1-3) ezetimibe (4),
and the PCSK9 inhibitor evolocumab (5) have been
demonstrated by large-scale clinical trials to reduce
cardiovascular events, reducing serum LDL cholesterol by
niacin (8,9), torcetrapib (13), and by evacetrapib (18) have
not been shown to reduce cardiovascular events.
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